

SYM TUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Concomitant Use of SYMTUZA with Paxlovid™ (nirmatrelvir tablets and ritonavir tablets)

SUMMARY

- Currently, there are no published data evaluating the concomitant use of SYMTUZA and Paxlovid.^{1,2}
- According to the Paxlovid Prescribing Information, patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated.²

CLINICAL DATA

- There are no published data evaluating the concomitant use of SYMTUZA and Paxlovid, which is nirmatrelvir tablets co-packaged with ritonavir (100 mg) tablets.^{1,2}
- According to the SYMTUZA Prescribing Information, SYMTUZA is a complete regimen for HIV-1 infection and co-administration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. Drug-drug interaction studies with other antiretroviral medications such as ritonavir were not conducted.¹
- According to the Paxlovid Prescribing Information, patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased Paxlovid or protease inhibitor adverse events.²

GUIDANCE DOCUMENTS

There are several resources that provide guidance for managing potential DDIs with ritonavir-boosted nirmatrelvir. These resources advise providers to exercise clinical judgement to assess the risks and benefits of therapy when managing patients on a case-by-case basis.

- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. Last Updated: July 21, 2023. In: COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/>
- Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group, University of Waterloo School of Pharmacy. Nirmatrelvir/Ritonavir (Paxlovid): What prescribers and pharmacists need to know. *Ontario COVID-19 Science Advisory Table*. 2022;3(58). <https://doi.org/10.47326/ocsat.2022.03.58.3.0>
- University of Liverpool. COVID-19 Drug Interactions. Available at: <https://www.covid19-druginteractions.org/checker>, Accessed 03 November 2022.
- Infectious Disease Society of America. Management of Drug Interactions with Nirmatrelvir/Ritonavir (Paxlovid): Resource for Clinicians. Last Updated: May 6, 2022. Available at: <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid/>

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 07 October 2023.

REFERENCES

1. SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SYMTUZA-pi.pdf>.
2. PAXLOVID (nirmatrelvir tablets and ritonavir tablets) [Prescribing Information]. New York: Pfizer Labs, Division of Pfizer, Inc; <https://labeling.pfizer.com/ShowLabeling.aspx?id=19599>.